Issue of Debt

RNS Number : 7389Y

AstraZeneca PLC

09 July 2008

 



Not for release, publication or distribution directly or indirectly in or into the United States, Canada, Australia or Japan

AstraZeneca releases final terms in relation to EUR 500 million eurobond

Following the pricing of the EUR 500 million eurobond transaction on 30 June 2008, AstraZeneca PLC, rated A1 (stable) by Moody's and AA- (stable) by Standard & Poor's, releases the final terms of the transaction.

To view the final terms, please click on the attached link.

http://www.rns-pdf.londonstockexchange.com/rns/7389Y_-2008-7-9.pdf

9 July 2008

Media Enquiries:

Steve Brown        [phone] (24 hours)    

Chris Sampson    [phone] (24 hours)    

Neil McCrae        [phone] (24 hours)    

Investor Enquiries UK:

Jonathan Hunt        [phone]    mob: [phone]

Mina Blair        [phone]      mob: [phone]

Karl Hard        [phone]      mob: [phone]

Investor Enquiries US:

Ed Seage            [phone]      mob: [phone]

Jorgen Winroth        [phone]      mob: [phone]

Peter Vozzo (MedImmune)      [phone]      mob: [phone]

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.  For more Information visit www.astrazeneca.com

About the announcement

This announcement is for information only and does not constitute an offer or invitation to subscribe for or purchase any securities.

The securities have not been, nor will they be, registered under the U.S. Securities Act of 1933, as amended (the 'Securities Act'), and no securities shall be offered or sold in the United States or to U.S. persons (as those terms are defined in Regulation S under the Securities Act) absent registration or an applicable exemption from the registration requirements of the Securities Act. There will be no public offering of the securities in the United States in connection with this transaction.

- Ends -

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

IODUUUMWMUPRGQB